NGS Blood Test Qualitatively Detects Thalassemia Mutations
By LabMedica International staff writers Posted on 05 Sep 2022 |
Thalassemia is an inherited blood disorder caused by an abnormal hemoglobin molecule, which inhibits the body’s ability to produce hemoglobin or red blood cells. Thalassemia occurs in approximately 4.4 out of every 10,000 live births throughout the world. The impact ranges from mild to severe, and can be life-threatening. It has been estimated that 5-7% of the world's population carries a mutated gene affecting the production or function of the hemoglobin molecule. Genomics has helped doctors better understand the abnormal hemoglobin molecule causing thalassemia and other hemoglobinopathies, thereby enabling more targeted treatments for patients. Now, a detection kit based on the combinatorial probe-anchor synthesis sequencing method, a next-generation sequencing (NGS) technology, can qualitatively detect α-thalassemia and β thalassemia mutations.
BGI Genomics’ (Shenzhen, China) Thalassemia Gene Detection Kit (Combinatorial Probe-Anchor Synthesis Sequencing Method) has recently obtained CE-IVDD approval, expanding the availability of genetic testing in the screening, diagnosis and treatment of thalassemia. Peripheral blood samples can be used for genetic screening of the general population for α and/or β thalassemia mutations, and diagnosis of patients and suspected patients with these mutations as well as abnormal hemoglobinopathy. In high-prevalence regions of the world, hemoglobin disorders such as thalassemia, constitute a serious medical and public health problem. These regions include the Mediterranean, the Middle Eastern and North African (MENA) region, Central Asia, the Indian subcontinent, and Southeast Asia.
"Screening for thalassemia through genetic testing is vital so that carriers and at-risk couples may be informed about their risk and the options for reducing it," said Jingjing Xiao, BGI Genomics Senior Product Manager. "These genetic tests are also the gold standard for the diagnosis of thalassemia."
Related Links:
BGI Genomics
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data